Breast Cancer

June 07, 2019
An ASCO Annual Meeting presentation showed the long-term safety and efficacy data of the phase III HERITAGE trial comparing biosimilar trastuzumab-dkst monotherapy vs trastuzumab monotherapy.
FDA Approval
March 12, 2019
The FDA has granted approval to a biosimilar product for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.